CDRH Preps New Program To Streamline Approval-To-Reimbursement Path
This article was originally published in The Gray Sheet
The device center is in the very early stages of launching the “CDRH Reimbursement Program,” planning to go beyond its current parallel-review collaboration with CMS to work with device firms, CMS and private payers to streamline the pathway from market approval to reimbursement.
You may also be interested in...
The agency's device center put out a request to health insurers to make themselves available to participate in FDA pre-submission meetings so that device firms, particularly start-ups, can better understand data expectations for coverage while companies are still designing studies to support FDA approval.
As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.
The firm’s corporate chief medical officer Michael Tarnoff says Covidien is developing a standard-of-care-disrupting device that would gain from early formal attention by CMS; he hopes to hear from the agencies on acceptance for parallel review by year’s end. Tarnoff said he thinks the program is underutilized.